Financial reports
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-K/A
2022 FY
Annual report (amended)
16 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
10 Mar 22
Current reports
8-K
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
28 Mar 24
8-K
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
29 Feb 24
8-K
Other Events
11 Dec 23
8-K
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update
9 Nov 23
8-K
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
14 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
9 Jun 23
8-K
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
25 May 23
8-K
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
23 May 23
8-K
Entry into a Material Definitive Agreement
17 May 23
8-K
Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update
9 May 23
Registration and prospectus
S-8
Registration of securities for employees
28 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
S-3
Shelf registration
14 Jun 23
424B5
Prospectus supplement for primary offering
25 May 23
S-8
Registration of securities for employees
16 Mar 23
424B7
Prospectus with selling stockholder info
12 Jan 23
S-3/A
Shelf registration (amended)
3 Jan 23
S-3
Shelf registration
29 Dec 22
D/A
$25.00 mm in other securities, sold $18.90 mm, 16 investors
7 Dec 22
D
$25.00 mm in other securities, sold $18.90 mm, 16 investors
28 Nov 22
Proxies
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
DEF 14A
Definitive proxy
21 Apr 22
DEF 14A
Definitive proxy
30 Mar 21
DEF 14A
Definitive proxy
2 Apr 20
PRER14A
Preliminary revised proxy
30 Mar 20
PRE 14A
Preliminary proxy
19 Mar 20
DEF 14A
Definitive proxy
28 Mar 19
DEF 14A
Definitive proxy
16 Aug 18
PRE 14A
Preliminary proxy
31 Jul 18
Other
EFFECT
Notice of effectiveness
26 Jun 23
CORRESP
Correspondence with SEC
21 Jun 23
UPLOAD
Letter from SEC
20 Jun 23
EFFECT
Notice of effectiveness
12 Jan 23
CORRESP
Correspondence with SEC
5 Jan 23
UPLOAD
Letter from SEC
4 Jan 23
EFFECT
Notice of effectiveness
6 Jan 22
CORRESP
Correspondence with SEC
3 Jan 22
CORRESP
Correspondence with SEC
30 Dec 21
UPLOAD
Letter from SEC
28 Dec 21
Ownership
4
Jerry Wan
23 Apr 24
4
CINDY JACOBS
23 Apr 24
4
Richard Alistair Stewart
23 Apr 24
4
John Bencich
23 Apr 24
SC 13G
FRANKLIN RESOURCES INC
11 Mar 24
4
Richard Alistair Stewart
6 Mar 24
4
John Bencich
6 Mar 24
SC 13G
Callahan Patrick J. III
27 Feb 24
4
Bridget A Martell
29 Jan 24
4
THOMAS BRAXTON KING
24 Jan 24